¹⁷⁷Lu-EDTMP is the ¹⁷⁷Lu equivalent of ¹⁵³Sm-Lexidronam developed for the same indication of bone pain palliation. This is a cheap way to bypass the IP of Quadramet although by now ¹⁵³Sm-EDTMP is available as a generic as well. ¹⁷⁷Lu-Lexidronam is mainly available in countries where ¹⁵³Sm-Quadramet was not available or too expensive.

¹⁷⁷Lu-EDTMP is, like ¹⁵³Sm-Lexidronam, indicated for bone pain palliation in cancer metastases (prostate). IAEA has supported the development of this Tracer and sponsored a multicenter clinical trial of ¹⁷⁷Lu-EDTMP.

Target/Mechanism: Bones

Carrier/Ligand: n/a

Radiation Type: beta electrons (β^–)